Correction to: Molecular mechanism of olesoxime-mediated neuroprotection through targeting α-synuclein interaction with mitochondrial VDAC

Correction to: Cellular and Molecular Life Sciences https://doi.org/10.1007/s00018-019-03386-w

In the published article, an error was noticed and this has been corrected with this erratum publication.

The correct Fig. 3 is as follows:

Fig. 3

αSyn co-localization with COX IV at the inner membrane is lost upon downregulation of VDAC1 expression. a Western blot of VDAC1 protein levels in differentiated SH-SY5Y cells transfected with a non-targeting sequence (NTC) siRNA or VDAC1–siRNA. GAPDH was used as a loading control and maintenance of αSyn overexpression under these conditions has been validated. b Quantification of the Western blot analysis as intensity ratios of VDAC1/GAPDH. Data are presented as mean ± SD (n = 3). In VDAC1–siRNA cells, the VDAC1/GAPDH ratio is significantly less than in NTC control. c Representative confocal images of PLA of VDAC1 and COX IV co-localization in controls and cells depleted of VDAC1, overexpressing αSyn alone or treated with olesoxime. The nuclei are stained in blue (DAPI) (× 63 objective, scale bar 20 µm). d Box plot represents the normalized distribution of PLA signals per cell, obtained from an average of 180 cells per experiment with a minimum of 60. The PLA signals were normalized to averaged PLA value measured in the NTC control cells of the corresponding experiment. The dashed line indicates a normalized PLA signal in NTC cells. Error bars indicate SD. At least 3 independent experiments were performed for each pairwise of antibodies. In b, d, **p < 0.01; NS (not significant): p ≥ 0.2; one-way ANOVA